 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H23BrCl2N4O |
| Molar mass | 522.27 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Surinabant (SR147778) is acannabinoid receptor type 1antagonist developed bySanofi-Aventis.[1] It is being investigated as a potential treatment fornicotineaddiction, to assistsmoking cessation. It may also be developed as ananorectic drug to assist with weight loss, however there are already several CB1 antagonists orinverse agonists on the market or under development for this application,[2] so surinabant is at present mainly being developed as an anti-smoking drug,[3] with possible application in the treatment of other addictive disorders such asalcoholism.[4][5] Other potential applications such as treatment ofADHD have also been proposed.[6]
A dose ranging study was done for smoking cessation[7] in 2012; it did not improve success rate, but reduced weight gain. Inhibition of THC effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.[8]
